How to buy BeiGene stock | $387.45

BeiGene Ltd is a biotechnology business based in the US. BeiGene shares (BGNE) are listed on the NASDAQ and all prices are listed in US Dollars. BeiGene employs 6,400 staff and has a trailing 12-month revenue of around 0.00.

BeiGene stock price (NASDAQ: BGNE)

Use our graph to track the performance of BGNE stocks over time.

BeiGene shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$387.45
52-week range	$219.20 - $426.56
50-day moving average	$365.51
200-day moving average	$332.59
Wall St. target price	$424.26
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-14.49

Buy BeiGene shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BeiGene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BeiGene price performance over time

Historical closes compared with the close of $387.45 from 2021-10-25

1 week (2021-10-19)	3.05%
1 month (2021-09-27)	2.72%
3 months (2021-07-27)	43.90%
6 months (2021-04-27)	19.80%

1 year (2020-10-26)	28.60%
2 years (2019-10-25)	178.96%
3 years (2018-10-26)	240.80%
5 years (2016-10-26)	1,077.30%

BeiGene financials

Revenue TTM	$947 million
Gross profit TTM	$-1,056,660,000
Return on assets TTM	-17.63%
Return on equity TTM	-42.68%
Profit margin	-138.52%
Book value	$38.93
Market capitalisation	$35.4 billion

TTM: trailing 12 months

Shorting BeiGene shares

There are currently 3.0 million BeiGene shares held short by investors – that's known as BeiGene's "short interest". This figure is 19.5% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting BeiGene shares can be evaluated.

BeiGene's "short interest ratio" (SIR)

BeiGene's "short interest ratio" (SIR) is the quantity of BeiGene shares currently shorted divided by the average quantity of BeiGene shares traded daily (recently around 378442.07240949). BeiGene's SIR currently stands at 8.01. In other words for every 100,000 BeiGene shares traded daily on the market, roughly 8010 shares are currently held short.

However BeiGene's short interest can also be evaluated against the total number of BeiGene shares, or, against the total number of tradable BeiGene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeiGene's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BeiGene shares in existence, roughly 30 shares are currently held short) or 0.0588% of the tradable shares (for every 100,000 tradable BeiGene shares, roughly 59 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BeiGene.

Find out more about how you can short BeiGene stock.

BeiGene share dividends

We're not expecting BeiGene to pay a dividend over the next 12 months.

BeiGene share price volatility

Over the last 12 months, BeiGene's shares have ranged in value from as little as $219.2 up to $426.56. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeiGene's is 0.7921. This would suggest that BeiGene's shares are less volatile than average (for this exchange).

BeiGene overview

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc.

Frequently asked questions

What percentage of BeiGene is owned by insiders or institutions?
Currently 20.121% of BeiGene shares are held by insiders and 60.762% by institutions. How many people work for BeiGene?
Latest data suggests 6,400 work at BeiGene. When does the fiscal year end for BeiGene?
BeiGene's fiscal year ends in December. Where is BeiGene based?
BeiGene's address is: 94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108 What is BeiGene's ISIN number?
BeiGene's international securities identification number is: US07725L1026 What is BeiGene's CUSIP number?
BeiGene's Committee on Uniform Securities Identification Procedures number is: 07725L102